pharmaphorum

JANUARY 13, 2025

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by Reuters to be worth around $442 million. Biogen has a longstanding alliance in place with Sage and co-markets Zurzuvae (zuranolone), which is FDA-approved for post-partum depression (PPD).

FDA 86

FDA Marketing 86

MedCity News

JANUARY 13, 2025

Johnson & Johnsons agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared first on MedCity News.

Prospecting 71

Prospecting Biopharma Pharma 71

PharmaTimes

JANUARY 13, 2025

Survey finds AI to enhance productivity and cut costs in the next 12 months

Pharmaceutical 72

Pharmaceutical 72

Pharmaceutical Technology

JANUARY 13, 2025

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

Healthcare 66

Healthcare Healthcare 66

Advertiser: ZoomInfo

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

Sales

PharmaTimes

JANUARY 13, 2025

Companies aim to provide new treatments for inflammatory conditions

Pharma 67

Pharma 67

pharmaphorum

JANUARY 13, 2025

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

60

60

pharmaphorum

JANUARY 13, 2025

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

Marketing 59

Marketing 59

Pharmaceutical Technology

JANUARY 13, 2025

After selling its PI3K program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotechs current shareholders.

59

59

pharmaphorum

JANUARY 13, 2025

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

59

59

Pharmaceutical Technology

JANUARY 13, 2025

CEO Albert Bourla expressed modest optimism for Pfizers 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

59

59

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Pharmaceutical Commerce

JANUARY 13, 2025

The latest news for pharma industry insiders.

Pharma 59

Pharma Healthcare Healthcare 59

Pharmaceutical Technology

JANUARY 13, 2025

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvaes launch in postpartum depression.

59

59

Pharmaceutical Commerce

JANUARY 13, 2025

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.

Pharma 59

Pharma 59

Pharmaceutical Technology

JANUARY 13, 2025

Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latters STAT6 programmes.

Pharma 59

Pharma 59

Advertiser: ZoomInfo

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

Sales Strategy

PharmaVoice

JANUARY 13, 2025

The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.

FDA 59

FDA 59

Pharmaceutical Technology

JANUARY 13, 2025

IDRxs lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Leads 59

Leads Patients 59

MedCity News

JANUARY 13, 2025

AI is the next big thing, and most developers want to protect those programs and systems. The answer is intellectual property protection and specifically patent protection. The post AI, IP and Your Healthcare: And You Thought the Doctors Exam Was Intrusive! appeared first on MedCity News.

Healthcare 107

Healthcare Healthcare Doctors Patients 107

Pharmaceutical Technology

JANUARY 13, 2025

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

59

59

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

European Pharmaceutical Review

JANUARY 13, 2025

GSK has agreed to acquire the biopharmaceutical firm IDRx Inc, a company focused on development of precision therapies for gastrointestinal stromal tumours (GIST). The deal is valued up to $1.15 billion, which includes an upfront payment of $1 billion. IDRx Inc could receive a further $150 million, subject to achievement of future regulatory approvals.

Biopharma 52

Biopharma Safety Patients Management 52

Pharmaceutical Technology

JANUARY 13, 2025

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

Medicine 59

Medicine 59

pharmaphorum

JANUARY 13, 2025

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

52

52

Pharmaceutical Technology

JANUARY 13, 2025

Mediar has entered into a global licensing agreement with Eli Lilly to progress MTX-463 into a Phase II trial for the treatment of IPF.

59

59

Advertiser: ZoomInfo

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

Prospecting

PharmaTech

JANUARY 13, 2025

Webinar Date/Time: Thu, Feb 13, 2025 11:00 AM EST

52

52

PharmExec

JANUARY 13, 2025

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas.

Healthcare 52

Healthcare Healthcare 52

PharmaTech

JANUARY 13, 2025

The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telixs portfolio, along with other novel targets currently in the discovery stage.

52

52

PharmExec

JANUARY 13, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Commerce

JANUARY 13, 2025

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

FDA 52

FDA 52

PharmExec

JANUARY 13, 2025

Under terms of the deal, GSK will also acquire IDRX-42, a tyrosine kinase inhibitor designed to treat both primary and secondary KIT mutations in patients with gastrointestinal stromal tumors.

Patients 52

Patients 52

PharmaTech

JANUARY 13, 2025

Pharmaceutical Technology chats about the increasing prevalence of challenging APIs in the development pipeline and the hurdles facing formulators and manufacturers as a result of this trend with Jens Schmidt from Lonza.

Manufacturing 52

Manufacturing Pharmaceutical 52

PharmExec

JANUARY 13, 2025

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52

Pharma 52

Advertiser: ZoomInfo

Sales and marketing leaders have reached a tipping point when it comes to using intent data — and they’re not looking back. More than half of all B2B marketers are already using intent data to increase sales, and Gartner predicts this figure will grow to 70 percent. The reason is clear: intent can provide you with massive amounts of data that reveal sales opportunities earlier than ever before.

Sales